Skip to content
Welcome, thoughtbot's Giant Robots listeners!Start here
UK Startups and Innovation
14NOV

J&J backs Trimtech seed to £35.6m

2 min read
18:53UTC

Trimtech Therapeutics extended its seed round to £35.6m after Johnson & Johnson Innovation and BGF added $14m and took board seats.

TechnologyDeveloping
Key takeaway

J&J and BGF bought board seats at Trimtech, backing UK biotech that domestic venture is not funding.

Trimtech Therapeutics, a Cambridge biotech, extended its seed round to £35.6m after Johnson & Johnson Innovation (JJDC), the US pharmaceutical group's venture arm, and BGF, a UK growth-capital investor, added $14m and both took board seats⁠1. The company designs targeted protein degraders, molecules that tag a disease-causing protein for the cell's own disposal system rather than merely blocking it, aimed at neurodegenerative and inflammatory disease.

The extension builds on a £25m seed led by Cambridge Innovation Capital in 2025. Strategic pharmaceutical capital, not UK venture, is funding the deep end here.

It is the same pattern as SAP taking a stake in Conduct to hedge its own migration deadline: a corporate investor buys a board seat to watch a technology it may later need, cheaper than building or acquiring it outright. For an early biotech, that visibility cuts both ways, bringing a route to market alongside an incumbent already inside the boardroom.

Deep Analysis

In plain English

Trimtech Therapeutics is a Cambridge company developing medicines that use 'targeted protein degraders', molecules that tag disease-causing proteins so the body's own cells break them down naturally, rather than simply blocking them the way most drugs do. The company has just topped up its earliest funding round to £35.6m after Johnson & Johnson's venture arm and BGF, a UK growth-capital investor, each put in money and took a seat on its board. A board seat gives an investor a formal say in how the company is run, which for a large drugmaker like Johnson & Johnson often signals interest in eventually licensing or buying the technology.

First Reported In

Update #10 · AI takes record 44% as UK equity shrinks

UKTN· 4 Jul 2026
Read original →
Causes and effects
This Event
J&J backs Trimtech seed to £35.6m
Corporate pharmaceutical capital, not UK venture, is funding the deep end of British biotech and buying boardroom visibility with it.
Different Perspectives
Association of Investment Companies (Richard Stone)
Association of Investment Companies (Richard Stone)
The trust industry body criticised the Budget for leaving Venture Capital Trust relief at 20%. It had lobbied for the 30% rate to return.
Tax Justice UK
Tax Justice UK
The campaign group opposed the 10% founders' rate as a giveaway to a small group of wealthy owners. It said the BADR cut should have gone further, to abolition.
techUK
techUK
The trade body set the new relief against the BADR cut, which halves the most a seller can save to £30,000. It says the Budget takes back with BADR part of what it gives founders.
Startup Coalition
Startup Coalition
The founder lobby group welcomed the Budget package for startups. It treats the new relief as the strongest government support for founders in years.
HM Treasury
HM Treasury
The Treasury created a 10% founders' relief on up to £10m of lifetime gains and expects about 600 people a year to use it. It says the relief rewards founders behind the UK's fastest-growing companies.
Abu Dhabi Investment Council
Abu Dhabi Investment Council
The Abu Dhabi Investment Council holds notes in Nscale's $3.36bn pre-IPO raise, beside Third Point, Apollo, Citadel and Nvidia. No British institution appears among the named holders of notes that convert into shares at Nscale's New York listing.

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Editorial standards.